Louisiana State Employees Retirement System Takes Position in Supernus Pharmaceuticals, Inc. $SUPN

Louisiana State Employees Retirement System purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 25,400 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,313,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SUPN. Rockefeller Capital Management L.P. raised its stake in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares during the period. Torren Management LLC purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at $49,000. Hantz Financial Services Inc. boosted its position in shares of Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 458 shares during the period. Global Retirement Partners LLC boosted its position in shares of Supernus Pharmaceuticals by 532.4% in the fourth quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock worth $70,000 after buying an additional 1,182 shares during the period. Finally, Vestcor Inc acquired a new stake in shares of Supernus Pharmaceuticals in the third quarter worth $67,000.

Wall Street Analyst Weigh In

SUPN has been the topic of several recent analyst reports. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $48.05 on Friday. The business has a 50 day simple moving average of $47.18 and a 200 day simple moving average of $49.50. Supernus Pharmaceuticals, Inc. has a 52 week low of $31.35 and a 52 week high of $59.68. The stock has a market cap of $2.79 billion, a price-to-earnings ratio of -94.22, a PEG ratio of 1.03 and a beta of 0.54.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.